XFUSION
18.5.2024 05:38:44 CEST | Business Wire | Press release
xFusion Digital Technologies Co., Ltd. (xFusion) dazzled attendees with its top-of-the-range computing products and solutions at the prestigious ISC High Performance 2024 event, hosted at the Congress Center Hamburg in Germany from May 13th to 15th. During the event, xFusion and fellow participants delved into the realms of AI and high performance computing (HPC) to explore their innovative applications and developmental trends, marking a significant convergence of minds and technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240516487957/en/
(Photo: xFusion)
Tab Tang , President of the Computing and Expansion at xFusion, delivered a keynote titled "Reinvent HPC in the Era of AI" during the Vendor Roadmap session on the 15th. He illuminated the pivotal role of smart computing in propelling industrial progress, highlighting the cooling challenges arising from high power and computing density, along with sustainability concerns. This necessitates clusters that are not only high-speed and low-latency but also highly reliable and stable. He also emphasized the transformative impact of AI on scientific endeavors, affirming xFusion's commitment to overcoming these challenges through pioneering software and hardware solutions. With a unified platform for both HPC and AI, xFusion aims to invigorate academic research and reshape the landscape of AI-driven HPC.
This year's ISC witnessed xFusion's spotlight on cutting-edge technologies like AI and HPC, presenting computing advancements characterized by openness, intelligence, eco-friendliness, and high-density. This compelling showcase drew attendees eager to delve deeper into these innovations.
At the event, xFusion proudly introduced FusionPoD for AI, a revolutionary rack-scale liquid-cooling cabinet poised to redefine computing paradigms. With its open architecture and support for diverse computing capabilities, FusionPoD for AI integrates groundbreaking architectural, software, and algorithmic innovations. It offers a fresh perspective by embracing multiple ecosystems, diversity, and low-carbon solutions to cater to the demanding requirements of AI large models and other HPC scenarios. This remarkable product delivers an unparalleled computing density of 64 GPUs and features a 100% liquid cooling native design with an impressively low pPUE of 1.06. xFusion also introduced the AI Space accelerator to both partners and customers, promising to expedite their AI application development and deployment.
xFusion stole the spotlight at ISC 2024 by showcasing its FusionOne HPC solution tailored for diverse HPC applications in education, scientific research, and manufacturing simulation. This state-of-the-art offering boasts adaptive characteristics, ensuring efficient, secure, reliable, and easily manageable operations. Notably, FusionOne HPC has already made waves with its deployment in the Weiming No. 2 Cluster at Peking University in 2023. This implementation has addressed the diverse needs of various disciplines, facilitating large-scale data processing and scientific computing while simultaneously reducing power consumption and fostering green research initiatives.
Beyond technological excellence, xFusion leads the charge in delivering comprehensive global business support through its dedicated team, bolstering remote O&M, cluster systems, and open architectural frameworks. Collaborating closely with partners, xFusion drives continuous innovation, fostering a thriving and sustainable HPC ecosystem. The current partnership with Bank Neo Commerce (BNC) in Indonesia marks a pivotal step in revolutionizing digital banking services. By offering agile, secure, and scalable digital infrastructure, xFusion empowers BNC to handle increasing transaction volumes and enhance customer interactions, fueling ongoing innovation and development in local digital banking services. FusionOnline, xFusion's remote intelligent O&M platform, is facilitating remote O&M in Europe, streamlining maintenance efforts while ensuring the long-term stability of user services.
Guided by the vision and mission of "Let Computing Serve You Better", xFusion has expanded its reach to over 100 countries and regions, cementing its status as a premier provider of computing infrastructures and services globally.
Looking to the future, xFusion remains optimistic about the potential of HPC to revolutionize industries and drive transformative innovation. In the era of AI, our ongoing contributions to the advancement of HPC underscore our commitment to shaping a brighter, more efficient, and interconnected world powered by our top-notch computing products and solutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240516487957/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 15:37:00 CEST | Press release
The new SpeechLive Legal AI Assistant reduces the administrative burden on legal professionals through customizable document drafting powered by speech recognition tuned for legal terminology Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
